Alphatec (NASDAQ:ATEC) (NASDAQ: ATEC) is a medical technology company focused on the development and commercialization of advanced spinal surgical products. The company’s mission centers on delivering safe, reproducible, and less invasive solutions for patients undergoing spinal fusion procedures. By integrating implants, instruments, and biologics into cohesive platforms, Alphatec aims to standardize minimally invasive techniques and improve clinical outcomes.
The company’s core product portfolio includes spinal implants, surgical instruments, and biologic materials designed for minimally invasive lateral, posterior and anterior lumbar interbody fusion approaches. Alphatec’s flagship platforms—such as the Zevo lateral system and the Trestle posterior system—combine proprietary retraction, implant delivery and neuromonitoring technologies to streamline workflow while preserving soft tissue. Its biologic offerings, including synthetic ceramics and allograft extenders, support robust fusion and bone healing.
Headquartered in Carlsbad, California, Alphatec serves spine surgeons and healthcare facilities throughout the United States, Europe and select international markets. The company maintains a direct sales and clinical support organization domestically, complemented by distributor partnerships overseas. Collaborations with leading academic medical centers and participation in multicenter clinical trials underpin Alphatec’s commitment to evidence‐based innovation and global regulatory clearances.
Founded in 2013 and publicly listed in 2016, Alphatec is led by President and Chief Executive Officer Vince Forlenza, a veteran of the medical device industry, alongside Chief Financial Officer Thomas Crow. Under their stewardship, the company has pursued a strategy of targeted acquisitions, robust research and development investment, and continual expansion of its product portfolio to advance minimally invasive spine care as the standard of treatment.
